Breaking News, Trials & Filings

Boehringer Starts Clinical Development of First-In-Class Fibrotic Disease Treatment

Preclinical studies have shown that anti-IL-11 treatment has the potential to stop – and even reverse fibrosis – in different fibrotic diseases.

Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers. The IL-11 inhibitor antibody is the first of its kind to reach clinical development stage and is based on a partnership between the company and Enleofen Bio Pte. Ltd., with a goal to improve patient outcomes. ‘Fibrotic disease’ is a term that covers a range of diseases ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters